Advancing Therapeutic Design in Gene and Cell Therapy with Dipen Sangurdekar

In this episode of Data in Biotech, Ross sits down with Dipen Sangurdekar, VP of Data Sciences at KSQ Therapeutics, to discuss the role of data-driven approaches in therapeutic design and development. The conversation explores the intersection of computational biology, machine learning, and bioinformatics in advancing personalized medicine and improving patient outcomes.

Dipen shares his journey in the industry, emphasizing the importance of integrating data science with biological research and the challenges associated with working in the rapidly evolving field of cell therapies. From hypothesis-driven research to leveraging multimodal data for actionable insights, this episode explores the nuances of using statistical methods and AI to enhance drug development.

Key Takeaways:

* Successful data science in therapeutics requires a deep understanding of both statistical methods and biological processes.
* High-dimensional but low-sample-size data demands a guided hypothesis-driven approach to avoid false positives.
* Data integration and collaboration between computational and biological teams are critical for generating meaningful insights.
* Emerging AI and machine learning tools are enhancing productivity but must be carefully applied in therapeutic research.
* Picking a problem you’re passionate about and going deep into it is crucial for long-term success in the field.

Connect with Our Guest:
Sponsor: CorrDyn, a data consultancy: https://www.corrdyn.com/
Find out more about KSQ Therapeutics: https://ksqtx.com/
Connect with Dipen on LinkedIn: https://www.linkedin.com/in/dipensangurdekar/

Connect with Us:
Follow the podcast for more insightful discussions on the latest in biotech and data science.
Subscribe and leave a review if you enjoyed this episode!